Recurrence of extreme serum analytes in consecutive pregnancies and association with obstetrical outcomes*

References

• Merkatz IR, Nitowsky HM, Macri JN, et al. An association between low maternal serum alpha fetoprotein and fetal chromosomal abnormalities. Am J Obstet Gynecol. 1984;148(7):886–894.
   PubMed Web of Science ®Google Scholar
• Cuckle HS, Wald NJ, Lindenbaum RH. Maternal serum alpha fetoprotein measurement: a screening test for Down syndrome. Lancet. 1984;1(8383):926–929.
   PubMed Web of Science ®Google Scholar
• Bogart MH, Pandian MR, Jones OW. Abnormal maternal serum chorionic gonadotropin levels in pregnancies with fetal chromosome abnormalities. Prenat Diagn. 1987;7(9):623–630.
   PubMed Web of Science ®Google Scholar
• Canick JA, Knight GJ, Palomaki GE, et al. Low second trimester maternal serum unconjugated oestriol in pregnancies with Down’s syndrome. BJOG. 1988;95(4):330–333.
   Web of Science ®Google Scholar
• Beekhuis JR, Van Lith JMM, De Wolf BTHM, et al. Increased maternal serum alpha fetoprotein and human chorionic gonadotropin in compromised pregnancies other than for neural tube defects or Down syndrome. Prenat Diagn. 1992;12(8):643–647.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Avgidou K, et al. First-trimester biochemical markers of aneuploidy and the prediction of small-for-gestational age fetuses. Ultrasound Obstet Gynecol. 2008;31(1):15–19.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Molina F, et al. First-trimester ultrasound and biochemical markers of aneuploidy and the prediction of preterm or early preterm delivery. Ultrasound Obstet Gynecol. 2008;31(2):147–152.
   PubMed Web of Science ®Google Scholar
• Spencer K, Cowans NJ, Nicolaides KH. Low levels of maternal serum PAPP-A in the first trimester and the risk of pre-eclampsia. Prenat Diagn. 2008;28(1):7–10.
   PubMed Web of Science ®Google Scholar
• Dugoff L, Hobbins JC, Malone FD, et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol. 2004;191(4):1446–1451.
   PubMed Web of Science ®Google Scholar
• Krantz D, Goetzl L, Simpson JL, et al. Association of extreme first-trimester free human chorionic gonadotropin-beta, pregnancy-associated plasma protein A, and nuchal translucency with intrauterine growth restriction and other adverse pregnancy outcomes. Am J Obstet Gynecol. 2004;191(4):1452–1458.
   PubMed Web of Science ®Google Scholar
• Brosens I, Pijnenborg R, Vercruysse L, et al. The “Great obstetrical Syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201.
   PubMed Web of Science ®Google Scholar
• Labarrere CA, DiCarlo HL, Bammerlin E, et al. Failure of physiologic transformation of spiral arteries, endothelial and trophoblast cell activation, and acute atherosis in the basal plate of the placenta. Am J Obstet Gynecol. 2017;216(3):287.e1–287.e16.
   PubMed Web of Science ®Google Scholar
• Morris RK, Cnossen JS, Langejans M, et al. Serum screening with Down’s syndrome markers to predict pre-eclampsia and small for gestational age: systematic review and meta-analysis. BMC Pregnancy Childbirth. 2008;8:33.
   PubMedGoogle Scholar
• Dugoff L, Society for Maternal-Fetal Medicine. First- and second-trimester maternal serum markers for aneuploidy and adverse obstetric outcomes. Obstet Gynecol. 2010;115(5):1052–1061.
   PubMed Web of Science ®Google Scholar
• Roman A, Desai N, Krantz D, et al. Maternal serum analytes as predictors of IUGR with different degrees of placental vascular dysfunction. Prenat Diagn. 2014;34(7):692–698.
   PubMed Web of Science ®Google Scholar
• Redman CW. Current topic: pre-eclampsia and the placenta. Placenta. 1991;12(4):301–308.
   PubMed Web of Science ®Google Scholar
• Halscott TL, Ramsey PS, Reddy UM. First trimester screening cannot predict adverse outcomes yet. Prenat Diagn. 2014;34(7):668–676.
   PubMed Web of Science ®Google Scholar
• Holding S, Cuckle H. Maternal serum screening for Down’s syndrome taking account of the result in a previous pregnancy. Prenat Diagn. 1994;14(4):321–322.
   PubMed Web of Science ®Google Scholar
• Spencer K. Between pregnancy biological variability of first trimester markers of Down syndrome: implications for screening in subsequent pregnancies. Prenat Diagn. 2001;21(6):445–447.
   PubMed Web of Science ®Google Scholar
• Spencer K. Between pregnancy biological variability of first trimester markers of Down syndrome and the implications for screening in subsequent pregnancies: an issue revisited. Prenat Diagn. 2002;22(10):874–876.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Huttly WJ, Rudnicka AR. Prenatal screening for Down syndrome: the problem of recurrent false-positives. Prenat Diagn. 2004;24(5):389–392.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Barnes IM, Birger R, et al. Effect on Down syndrome screening performance of adjusting for marker levels in a previous pregnancy. Prenat Diagn. 2006;26(6):539–544.
   PubMed Web of Science ®Google Scholar
• Lawrence JB, Oxvig C, Overgaard MT, et al. The insulin-like growth factor (IGF)-dependent IGF binding protein-4 protease secreted by human fibroblasts is pregnancy-associated plasma protein-A. Proc Natl Acad Sci U S A. 1999;96(6):3149–3153.
   PubMed Web of Science ®Google Scholar
• Gitlin D. Normal biology of alpha-fetoprotein. Ann N Y Acad Sci. 1975;259:7–16.
   PubMed Web of Science ®Google Scholar
• Wald NJ, Cuckle HS, Densem JW, et al. Maternal serum unconjugated oestriol as an antenatal screening test for Down’s syndrome. Br J Obstet Gynaecol. 1988;95(4):334–341.
   PubMedGoogle Scholar
• Berkeley AS, Killackey MA, Cederqvist LL. Elevated maternal serum alpha fetoprotein levels with breakdown in fetal–maternal–placental barrier. Am J Obstet Gynecol. 1983;146(7):859–861.
   PubMed Web of Science ®Google Scholar
• Oudejans CB, van Dijk M, Oosterkamp M, et al. Genetics of preeclampsia: paradigm shifts. Hum Genet. 2007;120(5):607–612.
   PubMed Web of Science ®Google Scholar
• Taché V, Baer RJ, Currier RJ, et al. Population-based biomarker screening and the development of severe preeclampsia in California. Am J Obstet Gynecol. 2014;211(4):377.e1–377.e8.
   PubMed Web of Science ®Google Scholar
• Yaron Y, Cherry M, Kramer RL, et al. Second-trimester maternal serum marker screening: maternal serum alpha fetoprotein, beta-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol. 1999;181(4):968–974.
   PubMed Web of Science ®Google Scholar
• Dugoff L, Hobbins JC, Malone FD, et al. Quad screen as a predictor of adverse pregnancy outcome. Obstet Gynecol. 2005;106(2):260–267.
   PubMed Web of Science ®Google Scholar